Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia

NCT04342962 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

25

Enrollment

OTHER

Sponsor class

Stopped poor enrollment

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: tagraxofusp

Sponsor

Gruppo Italiano Malattie EMatologiche dell'Adulto